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A B S T R A C T
HPMC capsules are made by a dipping process and a surface lubricant for the mould pins is an essential
processing aid for removing dried capsules shells. For the purpose of this study, the level was determined
by quantifying methyloleate (MO) a component found in the lubricant but not in the hypromellose
capsules. Here we investigated the inﬂuence of the lubricant, low (10.81 mg/capsule = 60 mg/kg MO),
medium (15.97 mg/capsule = 90 mg/kg MO) and high (23.23 mg/capsule = 127 mg/kg MO) content on
powder (binary mixture of salbutamol: lactose, 1:50 w/w) aerosolization properties was investigated.
Results indicated signiﬁcantly lower emitted dose from capsules with 60 mg/kg MO. Furthermore, the
90 and 127 mg/kg MO level of lubricant capsules produced almost double the Fine Particle Dose & Fine
Particle Fraction compared with the low level of lubricant. The data indicates that lubricant level within
capsules has an inﬂuence on deposition proﬁles and amount of drug remaining in capsule and inhaler
device after actuation. It is suggested lubricant levels greater than 60 mg/kg MO per capsule are required
to minimise powder retention within capsules and maximise deposition proﬁles. AFM (atomic force
microscopy) data suggest that internal surface roughness may be related with this phenomena.
ã 2015 Published by Elsevier B.V.
7 1. Introduction
8 Delivery of therapeutic agents via the pulmonary route has
9 gained increasing applications for lung diseases such as asthma
10 and COPD. Pulmonary delivery has many advantages including
11 delivery of medication directly to site of action, bypassing ﬁrst pass
12 metabolism in the liver (Geller, 2009; Labiris and Dolovich, 2003),
13 it is non-invasive and can achieve therapeutic outcome at lower
14 doses than administration via the oral route (Smith and Parry-
15 Billings, 2003).Q3
16 Dry powder inhaler (DPI) are able to deliver low and high doses
17 within the range of 5–500 mg, do not require co-ordination
18 between actuation and inspiration as with pMDI (Kaialy et al.,
19 2012). They have been developed since the 1960’s for a range of
20 conditions such as asthma and COPD using short and long acting
21 beta agonists, anti-cholinergic agents and corticosteroids drugs in
22 order to facilitate drug administration to the lungs via the
23 inhalation route (Atkins, 2005). Today there are currently more
24 than twenty commercially available DPI, both active and passive
25 (Chan et al., 2014). New active DPI incorporate additional
26mechanisms within the device to aid the ﬂuidization of the
27powder from the device and reduce the reliance on the patient’s
28inspiratory force. These mechanisms include vibration mesh which
29oscillates upon the patient’s inhalation, others include release of
30the powder formulation only when the patient has achieved the
31correct inspiratory force (Chan et al., 2014). Passive DPI have unit
32doses of drug in either blister packs or capsules, which contain the
33drug and a carrier, e.g. lactose, and drug deposition relies on the
34patient’s inspiratory force to de-aggregate the drug from the
35carrier (Chan et al., 2014; Kaialy et al., 2012; Zhou and Morton,
362012).
37The powder mass in the capsules allows ﬂexibility for the
38administration of low and high dose drugs within the range of 5 to
39500 mg. Examples of capsule based devices include the single unit
40HandiHaler1 (Boehringer-Ingelheim) (Islam and Gladki, 2008),
41TOBI1 PodhalerTM (tobramycin) and Colobreathe1 Turbospin1 for
42delivery of large doses (Claus et al., 2014), Breezhaler1 (Novartis),
43(Young et al., 2014) and novel multiple pre-metered unit-dose
44Flowcaps1 (Hovione) that contains up to 20 capsules (Friebel and
45Steckel, 2010). These devices are simple to use, cost-effective and
46can administer low and high doses. In addition, the capsule based
47devices improve patient compliance, as they can provide feedback
48to the patient in the form of a rattling sound, indicating correct* CorrespondingQ2 author. Fax: +44 0 151 231 2170
E-mail address: i.saleem@ljmu.ac.uk (I.Y. Saleem).
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49 inhalation ﬂow rate was achieved and passed through the device to
50 deliverQ4 the correct dose (Behara et al., 2014; Smith et al., 2010).
51 Moreover, the patient can visually check the capsule to determine
52 if the dose has been administered (Smith et al., 2010).
53 Hypromellose (HPMC) is used to make inhalation grade
54 capsules (Quali-V1-I) for use in DPI, as it is unaffected by moisture
55 content changes (Jones, 2008). Hence, it does not become brittle as
56 it loses moisture, a common phenomenon with gelatin capsules as
57 patients do not store them as directed resulting in broken capsules
58 and poor performance in their DPI (Nagata, 2002; Ogura et al.,
59 1998; Renswouw et al., 2010). In addition, it has also been shown
60 that HPMC capsules are less inﬂuenced by triboelectriﬁcation
61 which is common with gelatin capsules (Nakate et al., 2005).
62 Inhalation grade HPMC capsules are made from different grades of
63 raw material chosen for their puncturing properties (Torrisi et al.,
64 2013) and as a result have a slightly higher moisture content; 4.5–
65 6.5% compared to 4.0–6.0% in oral pharmaceutical grade capsules.
66 The HPMC Capsules are manufactured by dipping stainless steel
67 mould pins at room temperature into a warm solution of
68 hypromellose containing carrageenan as a network former and
69 potassium chloride as a network promoter (Jones, 2004). The
70 change in temperature causes the HPMC solution to gel and form a
71 ﬁlm on the surface of the mould pins. The ﬁlms are dried by passing
72 groups of pins through a series of drying kilns in which large
73 volumes of air at controlled temperature and humidity is blown
74 over them. As the ﬁlms dry they shrink on to the pins. To remove
75 them without damage it is essential for the mould pins to be coated
76 with a surface lubricant to act as a release aid. Capsules cannot be
77 manufactured without this lubricant (Jones, 2008). However, a
78 search of the literature only shows one study investigating the
79 inﬂuence of the amount of mould lubricant on the internal surfaces
80 of capsules in relation to the aerosolization properties of powders
81 from a capsule based DPI (Saim and Horhota, 2002). Furthermore,
82 this study relates to gelatin capsules and not HPMC.
83 The lubricant is a mixture of food and pharmaceutical grade
84 materials registered with regulatory authorities and the composi-
85 tion is proprietary for each capsule manufacturer. Hence for
86 quantitative analysis it is necessary to choose a component of the
87 lubricant which is not found in the HPMC capsules. In this study we
88 chose methyloleate (MO) as a marker for lubricant content
89 consisting of free fatty acids together with their esters. A number
90 of sample preparation methods have been proposed in the
91 literature to convert free fatty acids into their esters, such as
92 silylation (Woo and Kim, 1999) or reaction with alkyl chlorofor-
93 mates (Gimeno-Adelantado et al., 2001) as well as for trans-
94 esteriﬁcation of the triglycerides (Mason and Waller, 1964).
95 The aim of this study was to investigate the aerosolization
96 properties of dry powder formulations composed of inhalation
97 grade lactose and micronized salbutamol, ﬁlled in to size 3HPMC
98 inhalation grade capsules manufactured with 3 different lubricant
99 levels via an 8-pin inhaler device. Size 3HPMC capsules was chosen
100 because this is the size used in the pharmaceutical industry for
101 development of capsule-based DPI. For example the last signiﬁcant
102 developments in inhalation capsule-based devices, Ultibro and
103 Seebri Breezhaler, incorporate their respective dry powder
104 formulation into a size 3 capsule. This size capsule (0.8 mg/mL)
105 has a powder ﬁll weight of 225 mg. Furthermore, to the best of our
106 knowledge, the capsule inner surface lubricant content has not
107 been determined by GCMS or its distribution in HPMC capsules by
108 AFM. Hence, we describe a new technique with results obtained
109 using these methods in this study.
1102. Material and methods
1112.1. Materials
1128-pin monodose inhaler was provided by Plastiape S.p.a Italy.
113Hypromellose (HPMC) inhalation grade capsules, size 3 (Quali-V1-
114I) for this inhaler, manufactured using three different lubricant
115levels (satisfactory physical quality capsules were made at each
116level); low (10.81 mg/20 mg of blended powder within capsule =
11760 mg/kg MO), medium (15.97 mg/20 mg of blended powder
118within capsule = 90 mg/kg MO) and high (23.23 mg/20 mg of
119blended powder within capsule = 127 mg/kg MO) were obtained
120from Qualicaps1 Europe, S.A.U, Spain. Inhalation grade lactose
121(Respitose) was supplied by DFE Pharma, The Netherlands.
122Micronized salbutamol was obtained from Lusochimica, Spain.
123Methanol and 1-heptane sulphonic acid sodium salt were
124purchased from Sigma, UK. Methyloleate analytical standard,
125hexane and chloroform were from Sigma–Aldrich (St. Louis USA).
1261,2,3 Trichlorobenzene was purchased from Fluka and was used as
127internal standard. Trimethylsulfonium hydroxide solution,
128(TMSH), 0.25 M in methanol was used for GC derivatization.
1292.2. Determination of methyl oleate (MO) in capsules by gas
130chromatography mass spectrometry
131Gas chromatography mass spectrometry, GCMS, is the tech-
132nique most suitable for its qualitative and quantitative determi-
133nation after derivatization and extraction Q5into an organic solvent
134(Driscoll et al., 2009; Sutherland, 2007; Zhanga et al., 2014).
135Capsules inner lubricant content was evaluated by determining
136MO which was taken as a marker of the lubricant content using
137GCMS. Eleven HPMC capsules were weighted in a glass vial and
1385 mL of Hexane: chloroform, 60:40 (v:v) extraction solvent
139containing 10 mg/L of the internal standard was added. The vial
140was sonicated for 1 h in an ultrasonic bath; then 100 mL of the
141extract was transferred into a 2 mL vial for derivatization using
14250 mL of TMSH. The MO was identiﬁed by MS (Mass spectrometry)
143and was quantiﬁed using an internal calibration method with six
144points in the 0.5–20 mg/kg concentration range. 1 mL of the
145derivatized MO was injected in split less mode in the GCMS
146instrument.
1472.3. Preparation of inhalation grade lactose & powder mix
148Inhalation grade lactose and powder mix were prepared
149according to previously published method (Saleem et al., 2008)
150with slight modiﬁcations. Inhalation grade lactose was fractionat-
151ed by sieving with a sieve stack (250, 125, 90, 63, and 45 mm) using
152vibration amplitude of 40 for 10 min and collected on a 90 mm
153sieve to be used in all subsequent studies. Micronized salbutamol
154sulphate and lactose were mixed in a ratio of 1:50 (w/w) via
155geometric dilution to obtain a 2% binary blend. The formulations
156were blended with a Turbula1 orbital mixer (Glen Mills, Clifton,
157New Jersey) for 30 min at 46 rpm. The blend uniformity was
158determined by randomly selecting ﬁve 20 mg samples, and
159formulations were considered uniform when the coefﬁcient of
160variation (% CV) was 6%. Samples were analyzed using high-
161performance liquid chromatography (HPLC) method below (
162Section 2.4). Once blend uniformity was achieved 20  1 mg of
163blended powder was manually loaded into HPMC capsules (size 3)
164with different lubricant levels (low, medium and high) and stored
165in a humidity chamber (Sanyo Atmos Chamber) at 22 C and 40%
166RH for 2 weeks (Nine HPMC capsules were ﬁlled for each lubricant
167level at weeks 1 and 2).
2 I.Y. Saleem et al. / International Journal of Pharmaceutics xxx (2015) xxx–xxx
G Model
IJP 15038 1–6
Please cite this article in press as: Saleem, I.Y., et al., Investigation on the aerosol performance of dry powder inhalation hypromellose capsules
with different lubricant levels. Int J Pharmaceut (2015), http://dx.doi.org/10.1016/j.ijpharm.2015.07.034
168 2.4. In vitro aerosolization performance
169 For each lubricant level, three capsules (20  1 mg of powder
170 loaded into HPMC capsules (size 3)) corresponding to a dose of
171 408 mg were dispersed through a 8-pin DPI inhaler into a next
172 generation cascade impactor (NGI; MSP Corporation, Shoreview,
173 MN) at a ﬂow rate of 60 L min1 actuated for 4 s, with 15 mL of
174 mobile phase added to the pre-separator. This was repeated three
175 times (n = 3). Drug depositing in the capsule, inhaler, mouthpiece
176 adaptor, induction port, pre-separator and NGI stages were
177 collected by rinsing each component with mobile phase. This
178 was repeated at week 2 and the drug content was assessed via
179 HPLC method (Section 2.4).
180 The emitted dose (ED) was calculated as the total mass of drug
181 depositing in the mouthpiece, induction port, pre-separator, and
182 NGI stages. The ﬁne particle dose (FPD) was determined as the
183 mass of drug deposited in the NGI with aerodynamic diameters 
184 4.46 mm. The percentage ﬁne particle fraction (% FPF) of each dose
185 was the ratio of the drug mass depositing in the NGI (aerodynamic
186 diameter 4.46 mm) over the emitted dose. Mass median
187 aerodynamic diameter (MMAD) was calculated by subjecting
188 the inertial impaction data to log-probability analysis.
189 2.5. Chemical analysis
190 Capsules internal lubricant analysis were carried out by gas
191 chromatography coupled to mass spectrometry, GCMS, using a GC
192 7890 (Agilent Technologies, Palo Alto, CA, USA) and a 5975C
193 quadrupole mass spectrometer (Agilent Technologies, TX, USA). A
194 SupelcowaxQ6 10 (30 m  0.25 mm  0.25 mm ﬁlm thickness) fused
195 silica capillary column was used. The injection port temperature
196 was 240 C and the oven temperature program changed from 40 C
197 to 240 C at 10 C/min.
198 Salbutamol sulphate was analyzed by HPLC (Agilent Technolo-
199 gies) using a Kinetex C18 column (50  4.6 mm i.d. packed with
200 2.6 mm, phenomenex, UK). The mobile phase consisted of
201 methanol and 0.25% (w/v) 1-heptane sulphonic acid sodium salt
202 (45:55 v/v), the ﬂow rate was 1 mL/min, injection volume 10 mL,
203 temperature 25 C and wavelength was 200 nm. The retention time
204for salbutamol sulphate was 3 min and the limits of detection and
205quantiﬁcation were 0.60 and 1.12 mg/mL respectively.
2062.6. Morphology of inner capsule surface
207Atomic force microscopy, AFM, is a widely used technique for
208micro- and nanoscale material characterization creating a three
209dimensional image of a physical surface (Garcı’a and Pérez, 2002).
210A commonly employed measurement approach is based on
211tapping-mode AFM which involves a short and pulsed contact
212between the tip of an oscillating micro-cantilever and the sample
213surface. Vibrations of the cantilever tip are induced through dither
214piezo oscillations from which heights and phases are monitored for
215imaging purposes (García, 2010).
216The AFM (atomic force microscopy) experiments were made
217using a multimode Nanoscope III A (Bruker) in tapping mode in
218order to access surface topography. It is equipped with three
219scanners of 1, 1.5 and 150 m. Small pieces of 5  5 mm were cut and
220placed onto the Nanoscope probe. The instrument standard sample
221capsule probe was made of stainless steel but it was not suitable to
222handle the curved shape of a capsule; so, a special home-made
223support device was designed. Topographic measurements of the
224inner capsules surface at a ﬁxed scanning angle equal to zero were
225made using tapping mode (intermittent contact mode). The
226cantilever/tip assembly was sinuously vibrated by a piezo device
227mounted above it, and the oscillating tip slightly taped the surface
228at the resonant frequency of the cantilever with constant
229oscillating amplitude introduced in the vertical direction with a
230feedback loop keeping the average normal force constant.
231Measurements were made using a silicon probe (Veeco probe)
232with a spring constant of 5 N/m and a resonance frequency of
233150 kHz. All experiments were performed in air at ambient
234conditions. In order to stabilize thermally the piezo driver, the
235machine was turned on two hours before use. During each
236measurement a 15 15 mm surface was covered using a FESP tip.
2372.7. Statistical analysis
238The data obtained were analyzed statistically by one-way
239analysis of variance (ANOVA) with the Tukey’s comparison using
Fig. 1. Deposition of salbutamol sulphate remaining in capsules (A) and device (B) following aerosolisation at 60 L min1 from a 8-pin inhaler (Mean  SD, n = 3) **P < 0.05
(ANOVA/Tukey’s) Low (60 mg/kg MO) versus medium (90 mg/kg MO) & high (127 mg/kg MO) lubricant levels at weeks 1 and 2.
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240 Minitab 17 Statistical Software1 (Minitab Inc., PA, USA). Statistical
241 signiﬁcance were considered when p < 0.05. All values are
242 expressed as the mean  standard deviation.
243 3. Results and discussion
244 3.1. In vitro aerosolization performance
245 3.1.1. Comparing capsules and device
246 Comparing HPMC capsules (Fig. 1A) the results clearly indicate
247 a signiﬁcantly larger salbutamol retention in the low lubricant
248 capsule (week 1: 84.01 49.23 mg, week 2: 80.76  31.25 mg)
249 compared to the medium (week 1: 17.70  9.34 mg, week 2:
250 14.37  2.20 mg) and high lubricant capsules (week 1:
251 24.91 13.79 mg, week 2: 38.36  17.89 mg) (p < 0.05, ANOVA/
252 Tukey’s). However, there was no signiﬁcant difference regarding
253 salbutamol retention between medium and high lubricant
254 capsules at week 1 and 2. A similar trend was observed with
255 drug deposition remaining in the 8-pin inhaler (Fig. 1A). It is
256 evident from the data that lubricant level within the capsule is
257 important, with data suggesting lubricant levels between 90 and
258 127 mg/kg MO per capsule result in signiﬁcantly lower drug
259 deposition within the capsule and inhaler device. The high
260 salbutamol retention in low lubricant capsules occurred, because
261 during the removal of the capsules from the mould pins there is a
262 high degree of adhesion that causes roughness, which can be seen
263 by the mountain and deep valleys, as shown by AFM (see
264 Section 3.2). Hence during inhalation the salbutamol particles
265 become entrapped or lodged within these peaks and crevices
266 (Saim and Horhota, 2002). However, this effect is reduced
267 signiﬁcantly as the level of lubricant increases to greater than
268 90 mg/kg MO lubricant per capsule. This results in a smooth inner
269 surface of the capsule with less mountain and valleys (see
270 Section 3.2) as there is less adhesion during the removal from the
271moulding pins, and hence, reduction in contact between particles
272and crevices (Ibrahim et al., 2000; Saim and Horhota, 2002).
2733.1.2. Comparing emitted dose, ﬁne particle dose, ﬁne particle fraction
274& MMAD
275Fig. 2 shows the ED, FPD, FPF and MMAD of salbutamol
276aerosolized from an 8-pin inhaler at 60 L/min. The ED is
277signiﬁcantly lower for the low lubricant level capsules (week 1:
278223.73  42.72 mg, week 2: 217.69  63.85 mg) compared to the
279medium (week 1: 324.57  32.06 mg, week 2348.42 1.17 mg) and
280high lubricant capsules (week 1: 335.65  33.70 mg, week 2:
281309.35  37.67 mg) (p < 0.05, ANOVA/Tukey’s). These results were
282repeated for ﬁne particle dose (mg) (Fig. 2B) and ﬁne particle
283fraction (%) (Fig. 2C) where the values are almost twice that
284obtained using low lubricant capsules (p < 0.05, ANOVA/Tukey’s).
285This coincides with the high deposition of salbutamol remaining in
286the low lubricant capsules (Fig. 1A) and the device (Fig. 1A).
287Furthermore, the MMAD (mm) (Fig. 2D) is signiﬁcantly greater
288from low lubricant capsules (week 1: 3.37  0.78 mm, week 2:
2892.71 0.03 mm) compared to medium (week 1: 2.13  0.11 mm,
290week 2: 1.78  0.57 mm) and high (week 1: 2.12  0.16 mm, week 2:
2911.65  0.17 mm) (p < 0.05, ANOVA/Tukey’s). This also conﬁrms the
292low FPD and FPF within the lungs, due to large particle size and
293hence less drug depositing within the deep lungs.
2943.2. AFM studies
295Topographic plots from three capsule inner surfaces are
296represented in Fig. 3. They were taken as examples of the twelve
297capsules analyzed, which were selected at a low, medium and high
298concentrations that were previously determined by GCMS (Driscoll
299et al., 2009; Sutherland, 2007; Zhang et al., 2014).
300As can be seen, the topographic images show a mountain and
301deep valley distribution of the lubricant oil in the inner surface of
302the capsules. Similar results have been obtained using gelatin
Fig. 2. Emitted dose (mg) (A), Fine particle dose (mg) (B), Fine particle fraction (%) (C), MMAD (mm) (D) of salbutamol sulphate following aerosolisation at 60 L min1 from an
8-pin inhaler (Mean  SD, n = 3) **P < 0.05 (ANOVA/Tukey’s) Low (60 mg/kg MO) versus medium (90 mg/kg MO) & high (127 mg/kg MO) lubricant levels at weeks 1 and 2.
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303 capsules (Ibrahim et al., 2005). When the MO amount increased,
304 the inner surface appeared to be more homogenous (i.e. reduced
305 mountain and deep valley distribution) (Fig. 3A and C).
306 Four parameters derived from these plots (roughness, depth,
307 particle height and grain height) (Fig. 4) were used to obtain better
308 knowledge regarding inner capsule lubricant distribution. The
309 average from three different points on each capsule surface was
310 used to plot the different parameters versus MO concentration. It is
311 apparent (Fig. 4a) when the MO concentration increases, the
312 roughness, represented by Ra, decreased, indicating that
313homogeneity of capsule surface is higher when it is covered more
314completely with the lubricant.
315Reproducibility of the capsule inner surface can be evaluated by
316paying attention to two capsules groups containing three capsules
317with similar MO concentration, approximately 59 and 104 mg/kg
318respectively as indicated by the red circle in Fig. 4A. The
319reproducibility of the Ra parameter increases when MO concen-
320tration is higher. This seems to indicate that homogeneity of the
321lubricant inner surface is also enhanced when its concentration is
322higher.
Fig. 3. Topographical image of capsules inner surface containing (A) low (26 mg/kg MO), (B) medium (63 mg/kg MO) and (C) high (137 mg/kg MO) levels of methyloleate.
Fig. 4. Methyloleate concentration effect on (A) roughness, (B) Depth, (C) particle height and (D) grain height.
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323 Similarly, the average depth, particle height and height gain also
324 decreased when MO concentration increased (Fig. 4B–D), which
325 conﬁrmed the surface decreased when MO concentration
326 increases. In fact this tendency is also apparent in Fig. 4A–D, in
327 which dispersion of the respective parameters through an average
328 straight line decreases when the inner lubricant concentration
329 increases.
330 4. Conclusion
331 The study clearly indicates that the lubricant level inside
332 capsules has an inﬂuence on deposition proﬁles, amount of drug
333 remaining in capsule and inhaler device after actuation. The results
334 obtained suggest lubricant levels greater than 10.81 mg per capsule
335 (60 mg/kg MO) are beneﬁcial in decreasing drug deposition from
336 capsules in an 8-pin inhaler device, while more than doubling the
337 ﬁne particle dose and fraction. It seems this effect is related to the
338 capsule internal surface roughness. Measurements with AFM
339 indicated that homogeneity of the internal capsule surface is
340 higher when the inner lubricant concentration increases.
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